NCT02357602View on ClinicalTrials.gov

Dose Proportionality of TFV-DP After a Single Dose of GS-7340 in Women

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

November 30, 2016

Conditions
Healthy
Interventions
DRUG

GS-7340

Medication is supplied in 10 or 25mg tablets, so subjects will receive either 1/2 or one tablet in a single dose.

Trial Locations (1)

27599

University of North Carolina at Chapel Hill, Chapel Hill

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

University of North Carolina, Chapel Hill

OTHER

NCT02357602 - Dose Proportionality of TFV-DP After a Single Dose of GS-7340 in Women | Biotech Hunter | Biotech Hunter